<?xml version="1.0" encoding="UTF-8"?>
<ref id="B68-pharmaceuticals-13-00313">
 <label>68.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Li</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>S.-M.</given-names>
   </name>
   <name>
    <surname>Yu</surname>
    <given-names>X.-H.</given-names>
   </name>
   <name>
    <surname>Tang</surname>
    <given-names>S.-L.</given-names>
   </name>
   <name>
    <surname>Tang</surname>
    <given-names>C.-K.</given-names>
   </name>
  </person-group>
  <article-title>Coronavirus disease 2019 (COVID-19): Current status and future perspectives</article-title>
  <source>Int. J. Antimicrob. Agents</source>
  <year>2020</year>
  <volume>55</volume>
  <fpage>105951</fpage>
  <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105951</pub-id>
  <?supplied-pmid 32234466?>
  <pub-id pub-id-type="pmid">32234466</pub-id>
 </element-citation>
</ref>
